SCHEMBL2580978

SCHEMBL2580978

CCN(CC)CCN1C(=O)C(O)(c2ccccc2Cl)c2c(F)cc(C(N)=O)cc21

nearest known ligand 0.81

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
GHSR Q92847 17/20 0.81
HTR1A P08908 1/20 0.37
DRD3 P35462 1/20 0.37
OPRK1 P41145 1/20 0.37
HTR3A P46098 1/20 0.37
KCNH2 Q12809 1/20 0.37
TP53 P04637 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
POLB P06746 1/20 0.35
KDM4E B2RXH2 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2581094 0.91 GHSR (0.78) GHSRTP53POLBKDM4E
SCHEMBL2578797 0.91 GHSR (0.78) GHSRTP53POLBKDM4E
SCHEMBL6180161 0.90 GHSR (0.77) GHSRTP53POLBKDM4E
SCHEMBL2572828 0.89 GHSR (1.00) GHSRPOLBKDM4E
SCHEMBL29966946 0.89 GHSR (1.00) GHSRPOLBKDM4E
SCHEMBL6376444 0.89 GHSR (1.00) GHSRPOLBKDM4E
Hydrochloric Acid SCHEMBL17042306 0.89 GHSR (0.98) GHSRPOLBKDM4E
Hydrochloric Acid SCHEMBL17042307 0.89 GHSR (0.98) GHSRPOLBKDM4E
Hydrochloric Acid SCHEMBL29440072 0.89 GHSR (0.98) GHSRPOLBKDM4E
SCHEMBL2579393 0.88 GHSR (0.74) GHSRTP53POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2389941-A1 Growth-hormone secretagogues Elixir Pharmaceuticals, Inc. (US) 2011-11-30 EP disclosed
US-20080261873-A1 Growth-Hormone Secretagogues ELIXIR PHARMACEUTICALS, INC. (US) 2008-10-23 US disclosed
EP-1781311-A2 GROWTH-HORMONE SECRETAGOGUES Elixir Pharmaceuticals, Inc. (US) 2007-05-09 EP disclosed
WO-2006023608-A2 GROWTH-HORMONE SECRETAGOGUES ELIXIR PHARMACEUTICALS, INC. (US) 2006-03-02 WO disclosed
EP-1105376-B1 OXINDOLE DERIVATIVES AS GROWTH HORMONE RELEASERS SUMITOMO PHARMA (JP) 2005-02-09 EP disclosed
US-6576656-B1 Such as 1-(2-diethylaminoethyl)-4-trifluoromethyl-6-carbamoyl-3-hydroxy-3-(2 -chlorophenyl)oxindole; growth hormone releaser SUMITOMO PHARMACEUTICALS CO., LTD. (JP) 2003-06-10 US disclosed
EP-1105376-A1 OXINDOLE DERIVATIVES AS GROWTH HORMONE RELEASERS SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2001-06-13 EP disclosed
WO-2000010975-A1 OXINDOLE DERIVATIVES AS GROWTH HORMONE RELEASERS SUMITOMO PHARMACEUTICALS CO., LTD. (JP) 2000-03-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261873-A1 Growth-Hormone Secretagogues GHSR, GHRHR, GIPR GHSR 1/4885HTR1A 374/4885DRD3 1037/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.